放射性医薬品の世界市場-2030年までの産業動向と予測Global Radiopharmaceuticals Market - Industry Trends and Forecast to 2030 世界の放射性医薬品市場は、2022年の92億3,151万米ドルから2030年には153億1,705万米ドルに達し、2023年から2030年の予測期間中にCAGR 6.5%で成長すると予測される。この新しい市場レポートは、歴史的年2021年の... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー世界の放射性医薬品市場は、2022年の92億3,151万米ドルから2030年には153億1,705万米ドルに達し、2023年から2030年の予測期間中にCAGR 6.5%で成長すると予測される。この新しい市場レポートは、歴史的年2021年のデータを含み、計算の基準年は2022年、予測期間は2023年から2030年です。市場区分 国別(米国、カナダ、メキシコ、ドイツ、フランス、英国、スペイン、オランダ、ロシア、スイス、トルコ、オーストリア、ノルウェー、ハンガリー、リトアニア、アイルランド、ポーランド、その他の欧州地域、中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、ベトナム、その他のアジア太平洋地域、ブラジル、アルゼンチン、ペルー、その他の南米地域、南アフリカ、サウジアラビア、アラブ首長国連邦、エジプト、イスラエル、クウェート、その他の中東・アフリカ地域) - 産業動向と2030年までの予測 世界の放射性医薬品市場ダイナミクスの概要 推進要因 - 診断および臨床使用における放射性医薬品の需要拡大 阻害要因 - 放射性医薬品に関連する潜在的リスク 機会 - 放射性医薬品の研究開発費の増加 市場プレイヤー 世界の放射性医薬品市場に参入している主な市場プレーヤーを以下に挙げる: - カーディナル・ヘルス - ノバルティス社アドバンスト・アクセラレーター・アプリケーションズ - ランテウス - キュリウム社 - ゼネラル・エレクトリック社 - ジュビラント・ラジオファーマ社 - 中国リソトープ社 - ブラッコ - NTP - エッカート&ジーグラー - シャイン・テクノロジーズ LLC - エザックバシュモンロール - IBA ワールドワイド - グローバル・メディカル・ソリューションズ - BWXテクノロジーズ株式会社 - アイソトープス研究所 - コキー・ラジオファーマシューティカルズ社 - エバーグリーン・セラグノスティックス社 - アイソトープJSC - ファーマロジック・ホールディングス - シーメンスヘルスケアGmBH 目次TABLE OF CONTENTS1 INTRODUCTION 72 1.1 OBJECTIVES OF THE STUDY 72 1.2 MARKET DEFINITION 72 1.3 OVERVIEW OF THE GLOBAL RADIOPHARMACEUTICALS MARKET 72 1.4 LIMITATIONS 74 1.5 MARKETS COVERED 74 2 MARKET SEGMENTATION 77 2.1 MARKETS COVERED 77 2.2 GEOGRAPHICAL SCOPE 78 2.3 YEARS CONSIDERED FOR THE STUDY 79 2.4 CURRENCY AND PRICING 79 2.5 DBMR TRIPOD DATA VALIDATION MODEL 80 2.6 MULTIVARIATE MODELLING 83 2.7 PRODUCT TYPE LIFELINE CURVE 83 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 84 2.9 DBMR MARKET POSITION GRID 85 2.10 MARKET TESTING TYPE COVERAGE GRID 87 2.11 VENDOR SHARE ANALYSIS 88 2.12 SECONDARY SOURCES 89 2.13 ASSUMPTIONS 89 3 EXECUTIVE SUMMARY 90 4 PREMIUM INSIGHTS 93 4.1 PESTEL ANALYSIS 96 4.2 PORTER’S FIVE FORCES 97 4.3 PIPELINE ANALYSIS 98 4.4 PATENT ANALYSIS 99 4.5 DRUG TREATMENT RATE BY MATURED MARKETS 105 4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 106 4.7 PATIENT FLOW DIAGRAM 107 4.8 KEY PRICING STRATEGIES 107 4.9 KEY PATIENT ENROLLMENT STRATEGIES 108 5 LIST OF CYCLOTRONS 110 5.1 NORTH AMERICA 110 5.2 EUROPE 117 6 REGULATORY SCENARIO 129 6.1 NORTH AMERICA 129 6.2 EUROPE 129 6.3 ASIA-PACIFIC 130 6.4 MIDDLE EAST AND AFRICA 131 7 MARKET OVERVIEW 132 7.1 DRIVERS 134 7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE 134 7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS 134 7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES 135 7.2 RESTRAINTS 135 7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS 135 7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS 135 7.3 OPPORTUNITIES 136 7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS 136 7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION 136 7.4 CHALLENGES 137 7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 137 7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE 138 8 GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE 139 8.1 OVERVIEW 140 8.2 DIAGNOSTIC RADIOPHARMACEUTICALS 143 8.2.1 PET RADIOPHARMACEUTICALS 144 8.2.1.1 F-18 144 8.2.1.2 RU-82 144 8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS 144 8.2.2 SPECT RADIOPHARMACEUTICALS 145 8.2.2.1 TECHNETIUM-99M 145 8.2.2.2 GALLIUM-67 145 8.2.2.3 IODINE-123 145 8.2.2.4 THALLIUM-201 145 8.2.2.5 OTHER SPECT ISOTOPES 145 8.3 THERAPEUTIC RADIOPHARMACEUTICALS 146 8.3.1 BRACHYTHERAPY ISOTOPES 147 8.3.1.1 IODINE-125 147 8.3.1.2 PALLADIUM-103 147 8.3.1.3 CESIUM-131 147 8.3.1.4 IRIDIUM-192 148 8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES 148 8.3.2 BETA EMITTERS 148 8.3.2.1 IODINE-131 148 8.3.2.2 LUTHETIUM-177 148 8.3.2.3 SAMARIUM-153 148 8.3.2.4 YTTRIUM-90 148 8.3.2.5 RHENIUM-186 149 8.3.2.6 OTHER BETA EMITTERS 149 8.3.3 ALPHA EMITTERS 149 8.3.3.1 RA-223 149 8.3.3.2 OTHERS 149 9 GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION 150 9.1 OVERVIEW 151 9.2 DIAGNOSTIC 154 9.2.1 PET 155 9.2.1.1 ONCOLOGY 155 9.2.1.2 CARDIOLOGY 155 9.2.1.3 NEUROLOGY 155 9.2.1.4 OTHER PET APPLICATION 155 9.2.2 SPECT 156 9.2.2.1 CARDIOLOGY 156 9.2.2.2 BONE SCANS 156 9.2.2.3 THYROID APPLICATIONS 156 9.2.2.4 PULMONARY SCANS 156 9.2.2.5 OTHER SPECT APPLICATION 156 9.3 THERAPEUTIC 157 9.3.1 THYROID INDICATIONS 158 9.3.2 BONE METASTASIS 158 9.3.3 LYMPHOMA 158 9.3.4 ENDOCRINE TUMORS 158 9.3.5 OTHER INDICATIONS 158 10 GLOBAL RADIOPHARMACEUTICALS MARKET, BY SOURCE 159 10.1 OVERVIEW 160 10.2 NUCLEAR REACTORS 163 10.3 CYCLOTRONS 164 11 GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER 165 11.1 OVERVIEW 166 11.2 HOSPITALS 169 11.3 DIAGNOSTIC CENTERS 169 11.4 CANCER RESEARCH INSTITUTES 170 11.5 AMBULATORY SURGICAL CENTERS 171 11.6 OTHERS 172 12 GLOBAL RADIOPHARMACEUTICALS MARKET, BY REGION 173 12.1 OVERVIEW 174 12.2 NORTH AMERICA 179 12.2.1 U.S. 193 12.2.2 CANADA 202 12.2.3 MEXICO 211 12.3 EUROPE 220 12.3.1 GERMANY 231 12.3.2 U.K. 238 12.3.3 FRANCE 245 12.3.4 ITALY 252 12.3.5 SPAIN 259 12.3.6 BELGIUM 266 12.3.7 POLAND 273 12.3.8 RUSSIA 280 12.3.9 NORWAY 287 12.3.10 TURKEY 294 12.3.11 AUSTRIA 300 12.3.12 IRELAND 307 12.3.13 HUNGARY 314 12.3.14 NETHERLANDS 321 12.3.15 SWITZERLAND 328 12.3.16 REST OF EUROPE 335 12.4 ASIA PACIFIC 336 12.4.1 CHINA 347 12.4.2 AUSTRALIA 354 12.4.3 JAPAN 361 12.4.4 SOUTH KOREA 368 12.4.5 SINGAPORE 375 12.4.6 INDIA 382 12.4.7 INDONESIA 389 12.4.8 PHILIPPINES 396 12.4.9 THAILAND 403 12.4.10 MALAYSIA 410 12.4.11 VIETNAM 417 12.4.12 REST OF ASIA-PACIFIC 424 12.5 MIDDLE EAST AND AFRICA 425 12.5.1 SOUTH AFRICA 436 12.5.2 EGYPT 443 12.5.3 SAUDI ARABIA 449 12.5.4 U.A.E. 456 12.5.5 KUWAIT 463 12.5.6 ISRAEL 470 12.5.7 REST OF MIDDLE EAST AND AFRICA 477 12.6 SOUTH AMERICA 478 12.6.1 BRAZIL 489 12.6.2 ARGENTINA 496 12.6.3 CHILE 503 12.6.4 COLOMBIA 510 12.6.5 PERU 517 12.6.6 VENEZUELA 524 12.6.7 ECUADOR 531 12.6.8 REST OF SOUTH AMERICA 537 13 GLOBAL RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 538 13.1 COMPANY SHARE ANALYSIS: GLOBAL 538 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 539 13.3 COMPANY SHARE ANALYSIS: EUROPE 540 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 541 14 SWOT ANALYSIS 542 15 COMPANY PROFILE 543 15.1 CARDINAL HEALTH 543 15.1.1 COMPANY SNAPSHOT 543 15.1.2 REVENUE ANALYSIS 543 15.1.3 COMPANY SHARE ANALYSIS 544 15.1.4 PRODUCT PORTFOLIO 544 15.1.5 RECENT DEVELOPMENT 545 15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY 546 15.2.1 COMPANY SNAPSHOT 546 15.2.2 REVENUE ANALYSIS 546 15.2.3 COMPANY SHARE ANALYSIS 547 15.2.4 PRODUCT PORTFOLIO 547 15.2.5 RECENT DEVELOPMENT 547 15.3 LANTHEUS 548 15.3.1 COMPANY SNAPSHOT 548 15.3.2 REVENUE ANALYSIS 548 15.3.3 COMPANY SHARE ANALYSIS 549 15.3.4 PRODUCT PORTFOLIO 549 15.3.5 RECENT DEVELOPMENT 549 15.4 CURIUM 550 15.4.1 COMPANY SNAPSHOT 550 15.4.2 COMPANY SHARE ANALYSIS 550 15.4.3 PRODUCT PORTFOLIO 551 15.4.4 RECENT DEVELOPMENT 551 15.5 GENERAL ELECTRIC COMPANY 552 15.5.1 COMPANY SNAPSHOT 552 15.5.2 REVENUE ANALYSIS 552 15.5.3 COMPANY SHARE ANALYSIS 553 15.5.4 PRODUCT PORTFOLIO 553 15.5.5 RECENT DEVELOPMENT 553 15.6 BRACCO 554 15.6.1 COMPANY SNAPSHOT 554 15.6.2 PRODUCT PORTFOLIO 554 15.6.3 RECENT DEVELOPMENT 554 15.7 BWX TECHNOLOGIES. INC. 555 15.7.1 COMPANY SNAPSHOT 555 15.7.2 REVENUE ANALYSIS 555 15.7.3 PRODUCT PORTFOLIO 556 15.7.4 RECENT DEVELOPMENT 556 15.8 CHINA ISOTOPE & RADIATION CORPORATION 557 15.8.1 COMPANY SNAPSHOT 557 15.8.2 REVENUE ANALYSIS 557 15.8.3 PRODUCT PORTFOLIO 558 15.8.4 RECENT DEVELOPMENT 558 15.9 COQUI RADIOPHARMACEUTICALS CORP. 559 15.9.1 COMPANY SNAPSHOT 559 15.9.2 PRODUCT PORTFOLIO 559 15.9.3 RECENT DEVELOPMENT 559 15.10 ECKERT & ZIEGLER 560 15.10.1 COMPANY SNAPSHOT 560 15.10.2 REVENUE ANALYSIS 560 15.10.3 PRODUCT PORTFOLIO 561 15.10.4 RECENT DEVELOPMENT 561 15.11 ECZACIBAŞI-MONROL 562 15.11.1 COMPANY SNAPSHOT 562 15.11.2 PRODUCT PORTFOLIO 562 15.11.3 RECENT DEVELOPMENT 562 15.12 EVERGREEN THERAGNOSTICS, INC. 563 15.12.1 COMPANY SNAPSHOT 563 15.12.2 PRODUCT PORTFOLIO 563 15.12.3 RECENT DEVELOPMENT 563 15.13 GLOBAL MEDICAL SOLUTIONS 564 15.13.1 COMPANY SNAPSHOT 564 15.13.2 PRODUCT PORTFOLIO 564 15.13.3 RECENT DEVELOPMENT 564 15.14 IBA WORLDWIDE 565 15.14.1 COMPANY SNAPSHOT 565 15.14.2 REVENUE ANALYSIS 565 15.14.3 PRODUCT PORTFOLIO 566 15.14.4 RECENT DEVELOPMENT 566 15.15 INSTITUTE OF ISOTOPES 567 15.15.1 COMPANY SNAPSHOT 567 15.15.2 PRODUCT PORTFOLIO 567 15.15.3 RECENT DEVELOPMENT 567 15.16 ISOTOPE JSC 568 15.16.1 COMPANY SNAPSHOT 568 15.16.2 PRODUCT PORTFOLIO 568 15.16.3 RECENT DEVELOPMENT 568
SummaryThe global radiopharmaceuticals market is expected to reach USD 15,317.05 million by 2030 from USD 9,231.51 million in 2022, growing at a CAGR of 6.5% during the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030. Table of ContentsTABLE OF CONTENTS1 INTRODUCTION 72 1.1 OBJECTIVES OF THE STUDY 72 1.2 MARKET DEFINITION 72 1.3 OVERVIEW OF THE GLOBAL RADIOPHARMACEUTICALS MARKET 72 1.4 LIMITATIONS 74 1.5 MARKETS COVERED 74 2 MARKET SEGMENTATION 77 2.1 MARKETS COVERED 77 2.2 GEOGRAPHICAL SCOPE 78 2.3 YEARS CONSIDERED FOR THE STUDY 79 2.4 CURRENCY AND PRICING 79 2.5 DBMR TRIPOD DATA VALIDATION MODEL 80 2.6 MULTIVARIATE MODELLING 83 2.7 PRODUCT TYPE LIFELINE CURVE 83 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 84 2.9 DBMR MARKET POSITION GRID 85 2.10 MARKET TESTING TYPE COVERAGE GRID 87 2.11 VENDOR SHARE ANALYSIS 88 2.12 SECONDARY SOURCES 89 2.13 ASSUMPTIONS 89 3 EXECUTIVE SUMMARY 90 4 PREMIUM INSIGHTS 93 4.1 PESTEL ANALYSIS 96 4.2 PORTER’S FIVE FORCES 97 4.3 PIPELINE ANALYSIS 98 4.4 PATENT ANALYSIS 99 4.5 DRUG TREATMENT RATE BY MATURED MARKETS 105 4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 106 4.7 PATIENT FLOW DIAGRAM 107 4.8 KEY PRICING STRATEGIES 107 4.9 KEY PATIENT ENROLLMENT STRATEGIES 108 5 LIST OF CYCLOTRONS 110 5.1 NORTH AMERICA 110 5.2 EUROPE 117 6 REGULATORY SCENARIO 129 6.1 NORTH AMERICA 129 6.2 EUROPE 129 6.3 ASIA-PACIFIC 130 6.4 MIDDLE EAST AND AFRICA 131 7 MARKET OVERVIEW 132 7.1 DRIVERS 134 7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE 134 7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS 134 7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES 135 7.2 RESTRAINTS 135 7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS 135 7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS 135 7.3 OPPORTUNITIES 136 7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS 136 7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION 136 7.4 CHALLENGES 137 7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 137 7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE 138 8 GLOBAL RADIOPHARMACEUTICALS MARKET, BY TYPE 139 8.1 OVERVIEW 140 8.2 DIAGNOSTIC RADIOPHARMACEUTICALS 143 8.2.1 PET RADIOPHARMACEUTICALS 144 8.2.1.1 F-18 144 8.2.1.2 RU-82 144 8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS 144 8.2.2 SPECT RADIOPHARMACEUTICALS 145 8.2.2.1 TECHNETIUM-99M 145 8.2.2.2 GALLIUM-67 145 8.2.2.3 IODINE-123 145 8.2.2.4 THALLIUM-201 145 8.2.2.5 OTHER SPECT ISOTOPES 145 8.3 THERAPEUTIC RADIOPHARMACEUTICALS 146 8.3.1 BRACHYTHERAPY ISOTOPES 147 8.3.1.1 IODINE-125 147 8.3.1.2 PALLADIUM-103 147 8.3.1.3 CESIUM-131 147 8.3.1.4 IRIDIUM-192 148 8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES 148 8.3.2 BETA EMITTERS 148 8.3.2.1 IODINE-131 148 8.3.2.2 LUTHETIUM-177 148 8.3.2.3 SAMARIUM-153 148 8.3.2.4 YTTRIUM-90 148 8.3.2.5 RHENIUM-186 149 8.3.2.6 OTHER BETA EMITTERS 149 8.3.3 ALPHA EMITTERS 149 8.3.3.1 RA-223 149 8.3.3.2 OTHERS 149 9 GLOBAL RADIOPHARMACEUTICALS MARKET, BY APPLICATION 150 9.1 OVERVIEW 151 9.2 DIAGNOSTIC 154 9.2.1 PET 155 9.2.1.1 ONCOLOGY 155 9.2.1.2 CARDIOLOGY 155 9.2.1.3 NEUROLOGY 155 9.2.1.4 OTHER PET APPLICATION 155 9.2.2 SPECT 156 9.2.2.1 CARDIOLOGY 156 9.2.2.2 BONE SCANS 156 9.2.2.3 THYROID APPLICATIONS 156 9.2.2.4 PULMONARY SCANS 156 9.2.2.5 OTHER SPECT APPLICATION 156 9.3 THERAPEUTIC 157 9.3.1 THYROID INDICATIONS 158 9.3.2 BONE METASTASIS 158 9.3.3 LYMPHOMA 158 9.3.4 ENDOCRINE TUMORS 158 9.3.5 OTHER INDICATIONS 158 10 GLOBAL RADIOPHARMACEUTICALS MARKET, BY SOURCE 159 10.1 OVERVIEW 160 10.2 NUCLEAR REACTORS 163 10.3 CYCLOTRONS 164 11 GLOBAL RADIOPHARMACEUTICALS MARKET, BY END USER 165 11.1 OVERVIEW 166 11.2 HOSPITALS 169 11.3 DIAGNOSTIC CENTERS 169 11.4 CANCER RESEARCH INSTITUTES 170 11.5 AMBULATORY SURGICAL CENTERS 171 11.6 OTHERS 172 12 GLOBAL RADIOPHARMACEUTICALS MARKET, BY REGION 173 12.1 OVERVIEW 174 12.2 NORTH AMERICA 179 12.2.1 U.S. 193 12.2.2 CANADA 202 12.2.3 MEXICO 211 12.3 EUROPE 220 12.3.1 GERMANY 231 12.3.2 U.K. 238 12.3.3 FRANCE 245 12.3.4 ITALY 252 12.3.5 SPAIN 259 12.3.6 BELGIUM 266 12.3.7 POLAND 273 12.3.8 RUSSIA 280 12.3.9 NORWAY 287 12.3.10 TURKEY 294 12.3.11 AUSTRIA 300 12.3.12 IRELAND 307 12.3.13 HUNGARY 314 12.3.14 NETHERLANDS 321 12.3.15 SWITZERLAND 328 12.3.16 REST OF EUROPE 335 12.4 ASIA PACIFIC 336 12.4.1 CHINA 347 12.4.2 AUSTRALIA 354 12.4.3 JAPAN 361 12.4.4 SOUTH KOREA 368 12.4.5 SINGAPORE 375 12.4.6 INDIA 382 12.4.7 INDONESIA 389 12.4.8 PHILIPPINES 396 12.4.9 THAILAND 403 12.4.10 MALAYSIA 410 12.4.11 VIETNAM 417 12.4.12 REST OF ASIA-PACIFIC 424 12.5 MIDDLE EAST AND AFRICA 425 12.5.1 SOUTH AFRICA 436 12.5.2 EGYPT 443 12.5.3 SAUDI ARABIA 449 12.5.4 U.A.E. 456 12.5.5 KUWAIT 463 12.5.6 ISRAEL 470 12.5.7 REST OF MIDDLE EAST AND AFRICA 477 12.6 SOUTH AMERICA 478 12.6.1 BRAZIL 489 12.6.2 ARGENTINA 496 12.6.3 CHILE 503 12.6.4 COLOMBIA 510 12.6.5 PERU 517 12.6.6 VENEZUELA 524 12.6.7 ECUADOR 531 12.6.8 REST OF SOUTH AMERICA 537 13 GLOBAL RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 538 13.1 COMPANY SHARE ANALYSIS: GLOBAL 538 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 539 13.3 COMPANY SHARE ANALYSIS: EUROPE 540 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 541 14 SWOT ANALYSIS 542 15 COMPANY PROFILE 543 15.1 CARDINAL HEALTH 543 15.1.1 COMPANY SNAPSHOT 543 15.1.2 REVENUE ANALYSIS 543 15.1.3 COMPANY SHARE ANALYSIS 544 15.1.4 PRODUCT PORTFOLIO 544 15.1.5 RECENT DEVELOPMENT 545 15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY 546 15.2.1 COMPANY SNAPSHOT 546 15.2.2 REVENUE ANALYSIS 546 15.2.3 COMPANY SHARE ANALYSIS 547 15.2.4 PRODUCT PORTFOLIO 547 15.2.5 RECENT DEVELOPMENT 547 15.3 LANTHEUS 548 15.3.1 COMPANY SNAPSHOT 548 15.3.2 REVENUE ANALYSIS 548 15.3.3 COMPANY SHARE ANALYSIS 549 15.3.4 PRODUCT PORTFOLIO 549 15.3.5 RECENT DEVELOPMENT 549 15.4 CURIUM 550 15.4.1 COMPANY SNAPSHOT 550 15.4.2 COMPANY SHARE ANALYSIS 550 15.4.3 PRODUCT PORTFOLIO 551 15.4.4 RECENT DEVELOPMENT 551 15.5 GENERAL ELECTRIC COMPANY 552 15.5.1 COMPANY SNAPSHOT 552 15.5.2 REVENUE ANALYSIS 552 15.5.3 COMPANY SHARE ANALYSIS 553 15.5.4 PRODUCT PORTFOLIO 553 15.5.5 RECENT DEVELOPMENT 553 15.6 BRACCO 554 15.6.1 COMPANY SNAPSHOT 554 15.6.2 PRODUCT PORTFOLIO 554 15.6.3 RECENT DEVELOPMENT 554 15.7 BWX TECHNOLOGIES. INC. 555 15.7.1 COMPANY SNAPSHOT 555 15.7.2 REVENUE ANALYSIS 555 15.7.3 PRODUCT PORTFOLIO 556 15.7.4 RECENT DEVELOPMENT 556 15.8 CHINA ISOTOPE & RADIATION CORPORATION 557 15.8.1 COMPANY SNAPSHOT 557 15.8.2 REVENUE ANALYSIS 557 15.8.3 PRODUCT PORTFOLIO 558 15.8.4 RECENT DEVELOPMENT 558 15.9 COQUI RADIOPHARMACEUTICALS CORP. 559 15.9.1 COMPANY SNAPSHOT 559 15.9.2 PRODUCT PORTFOLIO 559 15.9.3 RECENT DEVELOPMENT 559 15.10 ECKERT & ZIEGLER 560 15.10.1 COMPANY SNAPSHOT 560 15.10.2 REVENUE ANALYSIS 560 15.10.3 PRODUCT PORTFOLIO 561 15.10.4 RECENT DEVELOPMENT 561 15.11 ECZACIBAŞI-MONROL 562 15.11.1 COMPANY SNAPSHOT 562 15.11.2 PRODUCT PORTFOLIO 562 15.11.3 RECENT DEVELOPMENT 562 15.12 EVERGREEN THERAGNOSTICS, INC. 563 15.12.1 COMPANY SNAPSHOT 563 15.12.2 PRODUCT PORTFOLIO 563 15.12.3 RECENT DEVELOPMENT 563 15.13 GLOBAL MEDICAL SOLUTIONS 564 15.13.1 COMPANY SNAPSHOT 564 15.13.2 PRODUCT PORTFOLIO 564 15.13.3 RECENT DEVELOPMENT 564 15.14 IBA WORLDWIDE 565 15.14.1 COMPANY SNAPSHOT 565 15.14.2 REVENUE ANALYSIS 565 15.14.3 PRODUCT PORTFOLIO 566 15.14.4 RECENT DEVELOPMENT 566 15.15 INSTITUTE OF ISOTOPES 567 15.15.1 COMPANY SNAPSHOT 567 15.15.2 PRODUCT PORTFOLIO 567 15.15.3 RECENT DEVELOPMENT 567 15.16 ISOTOPE JSC 568 15.16.1 COMPANY SNAPSHOT 568 15.16.2 PRODUCT PORTFOLIO 568 15.16.3 RECENT DEVELOPMENT 568
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
Data Bridge Market Research社の医薬分野での最新刊レポート
本レポートと同じKEY WORD(industry)の最新刊レポート
よくあるご質問Data Bridge Market Research社はどのような調査会社ですか?データブリッジマーケットリサーチ(Data Bridge Market Research)は500名以上の多様な分野のアナリストが所属するインドの調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/25 10:25 158.38 円 165.32 円 201.48 円 |